| Related Articles |
Laxative Use in Inpatients on Oxycodone/Naloxone Prolonged Release and Oxycodone Prolonged Release for Cancer and Non-cancer Pain.
J Pain Palliat Care Pharmacother. 2019 Feb 08;:1-8
Authors: Patel J, Lucas CJ, Margalit M, Martin JH
Abstract
OBJECTIVE: To examine the laxative prescriptions in hospital inpatients with cancer and non-cancer pain on oxycodone compared to oxycodone plus naloxone combination.
DESIGN: Retrospective case note review.
SETTING: A palliative care inpatient unit and a general medical ward in a large tertiary referral hospital.
PARTICIPANTS: Eighty-four patients receiving oxycodone or combination oxycodone/naloxone on general medical (45 patients) and palliative care wards (39 patients).
MAIN OUTCOME MEASURES: The primary recorded outcomes were regular opioid dose (milligrams per day) and number of prescribed laxatives (type, doses, and frequency per day).
RESULTS: Sixty-three (75%) patients in the study were on at least one laxative. In the general medicine inpatients, those on combined oxycodone/naloxone received on average 3.7 laxative doses per day compared to the oxycodone patients receiving 1.6 doses a day. In the palliative medicine population, both groups received a similar number of laxatives, despite the oxycodone/naloxone patients being on lower opioid doses.
CONCLUSION: This retrospective study of hospital inpatients with cancer and non-cancer pain found that laxative use was not reduced in those on combined oxycodone/naloxone compared to oxycodone alone, suggesting that despite the interpretations of the clinical trials in the phase IV setting, the addition of naloxone had no effect on reducing laxative use.
PMID: 30735070 [PubMed - as supplied by publisher]